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________________________________________________________________________________________
Background: Myeloma cells cause abnormal 
osteoclast formation and osteolysis.  
Results: Myeloma cells up-regulate AKT in 
osteoclast precursors and promote osteoclast 
formation. Systemic AKT inhibition blocks the 
myeloma-induced osteolysis and tumor growth 
in bone. 
Conclusion: AKT is critical for the myeloma 
promotion of osteoclast formation and 
osteolysis.   
Significance: AKT could be a useful target for 
treating patients with myeloma bone disease. 
SUMMARY 
Abnormal osteoclast formation and 
osteolysis are a hallmark of multiple 
myeloma (MM) bone disease, yet the 
underlying molecular mechanisms are 
incompletely understood. Here we show that 
the AKT pathway was up-regulated in 
primary bone marrow monocytes (BMM) 
from MM patients, which resulted in 
sustained high expression of receptor 
activator of NF-kappaB (RANK) in 
osteoclast precursors. The up-regulation of 
RANK expression and osteoclast formation 
in the MM BMM cultures was blocked by 
AKT inhibition. Conditioned media from 
MM cell cultures activated AKT and 
increased RANK expression and osteoclast 
formation in BMM cultures. Inhibiting AKT 
in cultured MM cells decreased their growth 
and ability to promote osteoclast formation. 
Of clinical significance, systemic 
administration of an AKT inhibitor 
LY294002 blocked the formation of tumor 
tissues in the bone marrow cavity and 
essentially abolished the MM-induced 
 http://www.jbc.org/cgi/doi/10.1074/jbc.M113.469973The latest version is at 
JBC Papers in Press. Published on September 4, 2013 as Manuscript M113.469973
 Copyright 2013 by The American Society for Biochemistry and Molecular Biology, Inc.
This is the author's manuscript of the article published in final edited form as: 
Cao, H., Zhu, K., Qiu, L., Li, S., Niu, H., Hao, M., ... & Xiao, G. (2013). Critical role of AKT protein in myeloma-induced osteoclast 
formation and osteolysis. Journal of Biological Chemistry, 288(42), 30399-30410. http://dx.doi.org/10.1074/jbc.M113.469973
2 
osteoclast formation and osteolysis in SCID 
mice. The level of activating transcription 
factor 4 (ATF4) protein was up-regulated in 
the BMM cultures from MM patients. 
Adenoviral overexpression of ATF4 
activated RANK expression in osteoclast 
precursors. These results demonstrate a new 
role of AKT in the MM promotion of 
osteoclast formation and bone osteolysis 
through, at least in part, the 
ATF4-dependent up-regulation of RANK 
expression in osteoclast precursors.  
______________________________________ 
Multiple myeloma bone disease (MMBD) 
is characterized by progressive osteolysis 
associated with abnormally increased osteoclast 
formation and activation. Up to 90% of patients 
with multiple myeloma (MM) develop osteolytic 
lesions (1), which cause major clinical problems 
such as bone pain, pathological fractures, spinal 
cord compression, and hypercalcemia of 
malignancy (2-4). Studying the underlying 
molecular mechanisms will help to develop new 
therapeutic targets to treat osteolytic lesions and 
related complications in MM patients.  
Osteoclasts originate from cells in the 
monocyte/macrophage lineage (5). Osteoclast 
formation and maturation are tightly regulated 
by osteoblast/stromal 
cell/osteocyte/hypertrophic chondrocyte-derived 
factors such as M-CSF, RANKL, and OPG. 
OPG is a soluble decoy receptor that blocks 
RANKL binding to RANK and thereby inhibits 
osteoclast differentiation (6,7). M-CSF binds to 
its receptor CSF1R on early macrophage lineage 
cells and activates RANK expression (8). This is 
a critical step for generating osteoclast 
precursors and early osteoclast differentiation. 
RANKL then binds to RANK on osteoclast 
precursors and recruits TRAF6, which results in 
the activation of multiple signaling pathways 
including IKK complexes (IKKα,β,γ and 
NIK-IKKα) and MAPKs (ERK1/2, p38, and 
JNK) (9,10), leading to activation of critical 
transcription factors such as NF-κB and c-FOS, 
and NFATc1 and eventually osteoclast 
formation (10-12).  
Abnormal osteoclast formation and 
activation are mediated by factors produced and 
induced by tumor cells (13). For example, breast 
cancer cells-produced parathyroid 
hormone-related protein (PTHrP) induces 
osteoclast formation through up-regulation of 
RANKL by osteoblasts (14,15). Further, the 
NF-κB pathway in breast cancer cells promotes 
osteolytic bone metastasis by activating 
osteoclast formation via up-regulation of 
granulocyte-macrophage colony-stimulating 
factor (GM-CSF) (16). Monocyte chemotactic 
protein-1 (MCP-1) mediates prostate cancer- and 
lung cancer-induced osteoclast formation and 
bone resorption (17,18). Macrophage 
inflammatory protein (MIP)-1α promotes the 
development of osteolytic lesions in MM 
patients (19,20). Enhanced RANKL expression 
plays an important role in tumor-induced 
osteoclast formation and bone destruction 
(13,21).  However, molecular mechanisms 
whereby the MM cells promote osteoclast 
formation and activation and osteolysis are not 
completely understood.  
AKT, also known as protein kinase B 
(PKB), is a serine/threonine-specific protein 
kinase that plays a critical role in multiple 
cellular processes such as cell proliferation and 
survival and migration, glucose metabolism, and 
gene transcription (22,23). Accumulative 
evidence shows that the PI3K/AKT pathway 
plays a critical role in activating osteoclast 
differentiation (24,25). However, if and how 
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AKT mediates the MM-induced osteoclast 
formation and osteolysis has not been addressed. 
EXPERIMENTAL PROCEDURES 
Reagents-Tissue culture media, fetal 
bovine serum, and horse serum were obtained 
from Thermo Scientific HyClone (Logan, Utah). 
LY294002 was purchased from LC Laboratories 
(Worburn, MA), ascorbic acid and DMSO from 
Sigma Aldrich (St. Louis, MO), human 
recombinant M-CSF, RANKL, and TNF-α from 
R&D Systems Inc. (Minneapolis, MN). All 
other chemicals were of analytical grade. 
Human bone marrow samples-Bone 
marrow aspirates were collected in heparin 
from normal donors (ND) and patients with 
MM. Protocols were approved by the 
respective IRB committees of the University of 
Pittsburgh and the Institute of Hematology & 
Blood Diseases, Chinese Academy of Medical 
Sciences.  
DNA constructs, transfection, and 
adenoviral infection- pCMV/β-gal, 
pCMV/ATF4, pCMV/AKT-CA, and wild-type 
and mutant p4OSE1-luc plasmids (an ATF4 
reporter plasmid) were previously described 
(26,27). Rank-luc reporter plasmid was 
constructed by PCR subcloning of a -1073/+79 
mouse Rank gene promoter into the pGL3-luc 
vector (Promega, Madison, WI) in the project 
laboratory. For transfection experiments, the 
amounts of plasmid DNAs were balanced as 
necessary with β-galactosidase expression 
plasmid such that the total DNA was constant 
in each group. Adenoviruses expressing ATF4 
or EGFP were described previously (28,29). 
The amount of adenovirus was balanced as 
necessary with a control adenovirus expressing 
EGFP such that the total amount was constant 
in each group.  
Gene expression studies-RNA isolation 
and reverse transcription (RT) were previously 
described (30). Quantitative real-time RT-PCR 
analysis was performed to measure the relative 
mRNA levels using SYBR Green kit (Bio-Rad 
Laboratories Inc.). Melting curve analysis was 
used to confirm the specificity of the PCR 
products. Four to six samples were run for each 
primer set. The levels of mRNA were 
calculated by the ddCt method. Samples were 
normalized to Gapdh expression. The DNA 
sequences of human and mouse primers used 
for qPCR were summarized in Tables 1 and 2. 
Western blot analysis was performed as 
previously described (26,30). Antibodies used 
are from the following sources: antibodies 
against NFATc1, c-FOS, RANK, ATF4 and 
anti-rabbit or anti-mouse antibodies conjugated 
with horseradish peroxidase from Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA), 
antibodies recognizing phosphorylated and 
total AKT and PU.1 from Cell Signaling 
Technology Inc. (Beverly, MA), and mouse 
monoclonal antibody against β-actin from 
Sigma Aldrich.  
In vitro osteoclast assays-For osteoclast 
studies using bone marrow cells from humans, 
nonadherent BMMs were isolated from MM 
patients and normal donors (NDs). For 
undifferentiated cultures, cells were cultured in 
the proliferation media (α-MEM media 
containing 20% horse serum and 10 ng/ml 
human recombinant M-CSF) for 10d. For 
differentiation studies, cells were cultured in 
the differentiation media (proliferation media 
containing 50 ng/ml human recombinant 
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RANKL) for 21d, followed by TRAP or 23C6 
staining or gene expression studies. The 
anti-23C6 antibody, which recognizes the 
αvβ3 integrin, a receptor for vitronectin, on 
osteoclasts, was described previously (31-33). 
The TRAP- or 23C6-positive multinucleated 
cells (MNCs) (≥3 nuclei) were scored using an 
inverted microscope. For osteoclast studies 
using primary mouse bone marrow cells 
(BMMs), nonadherent BMMs were isolated 
from total bone marrow cells and cultured on 
tissue culture dishes for 48 h. For 
differentiation, cells were first cultured in the 
proliferation media (α-MEM containing 10% 
FBS and 10 ng/ml M-CSF) for 3d and switched 
to differentiation media (proliferation media 
plus 50 ng/ml RANKL) for 5-7d, followed by 
TRAP staining or gene expression studies. The 
TRAP-positive MNCs (≥3 nuclei) were scored 
using an inverted microscope. 
Mouse model and histological analysis 
and bone histomorphometry-For intratibial 
injection, both left and right tibiae of 
4-weeks-old male SCID mice (10 mice/group 
or 20 tibiae/group) were injected with 1x106 
5TGM1 cells in 20 µl PBS or 20 µl PBS alone 
(control group without MM injection). One 
week later, mice were subcutaneously injected 
with LY294002 (40 mg/kg body weight) or 
vehicle (DMSO) twice a week for 3 weeks. 
Protocols were approved by the Institutional 
Animal Care and Use Committee (IACUC) of 
the Nankai University. All specimens were 
fixed in 10% formalin at 4 oC for 24 h, 
decalcified in 10% EDTA (pH 7.4) for 10-14d, 
and embedded in paraffin. Then serial sections 
were prepared and stained with hematoxylin 
and eosin. Sections of tibiae from each group 
were used for TRAP staining as described 
previously (34). Bone histomorphometry such 
as osteoclast surface/bone surface (Oc.S/BS) 
and osteoclast number/bone perimeter 
(Oc.Nb/BPm) of tibiae was measured using an 
Image Pro Plus 7.0 software as previously 
described (25,35).  
Statistical Analysis-Data was analyzed 
with a GraphPad Prism software (4.0) (San 
Diego, CA). A one-way ANOVA analysis was 
used followed by the Tukey test. Results were 
expressed as means ± standard deviation (SD). 
Differences with a P <0.05 was considered as 
statistically significant. All experiments were 
repeated at least 2 times and similar results 
were obtained. 
RESULTS 
MM activates osteoclast formation in 
primary bone marrow monocyte (BMM) cultures 
in the presence and absence of exogenously 
added RANKL. To study the mechanisms 
whereby MM cells activate osteoclast formation, 
we measured osteoclast differentiation in 
primary BMM cultures from MM patients in 
vitro compared to BMM cultures from normal 
donors (ND) with or without addition of 
exogenous RANKL. We measured the numbers 
of TRAP-positive multinucleated osteoclasts 
(MNCs) generated by each. Results showed that 
the number of TRAP+ MNCs (≥3 nuclei) in the 
RANKL-differentiated MM BMM cultures was 
dramatically increased compared to that in the 
ND BMM cultures (Figure 1, A and B). The 
MNCs formed in the RANKL-differentiated 
MM BMM cultures were much larger than those 
from the ND BMM cultures (Fig 1B). 
Surprisingly, we found a number of TRAP+ 
MNCs in the MM BMM cultures in the absence 
of exogenously added RANKL, which were 
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absent from the ND BMM control cultures (Fig 
1, A and C). This could result from potential 
contamination of osteoblasts and stromal cells 
and bone marrow lymphocytes, which produce 
RANKL and OPG (36). For this reason, we 
measured the expression levels of both factors 
by qPCR analysis. Results showed that, although 
both mRNAs were detected in both cultures, the 
RANKL/OPG ratio was actually reduced in the 
MM versus ND cultures (Fig 1D). Therefore, the 
enhanced osteoclast formation in the MM 
cultures is not due to increased RANKL and/or 
reduced /OPG expression produced by cells in 
the cultures. qPCR analysis showed that the 
mRNA levels of osteoclast differentiation 
marker genes including those encoding 
cathepsin K (Cat K), integrin β3 (β3), nuclear 
factor of activated T cells (NFAT) c1 (a master 
regulator of osteoclast differentiation), and 
matrix metalloproteinase-9 (MMP-9) were all 
significantly increased in the differentiated MM 
relative to ND BMM cultures (Fig 1E). The 
mRNA level of c-FMS, the gene that encodes 
the receptor for the macrophage 
colony-stimulating factor (CSF-1R), was 
slightly but significantly increased in the 
RANKL-differentiated MM versus ND BMM 
cultures (Fig 1E). In contrast, the mRNA level 
of PU.1 (an Ets family transcription factor that 
regulates osteoclast differentiation) was not 
different in the RANKL-differentiated MM and 
ND BMM cultures (Fig 1E). Western blot 
analysis revealed that the levels of NFATc1 
protein were increased in the 
RANKL-differentiated BMM cultures from 5 
MM patients compared to those in 5 NDs (Fig 
1F). Collectively, these results suggest that 
osteoclast differentiation capacity of the MM 
BMMs is increased in both RANKL-dependent 
and RANKL-independent manners.  
Sustained high expression of RANK is a 
major feature of the BMMs from MM patients. 
To study the early molecular events in the MM 
BMM cultures, we measured the expression 
levels of genes that are known to regulate early 
osteoclast differentiation in undifferentiated 
BMM cultures from MM patients and NDs. 
Results showed that the level of RANK mRNA 
was increased by more than 10-fold in 
undifferentiated BMM cultures from MM 
patients compared to that from NDs (Fig 2A). In 
contrast, the levels of c-FMS, PU.1, c-FOS, 
TRAF6 and DAP-12 mRNAs were not 
significantly increased in the undifferentiated 
MM versus ND BMM cultures (Fig 2A). 
Western blot analysis confirmed that the level of 
RANK protein was increased in the 
undifferentiated MM relative to ND BMM 
cultures (Fig 2B). Importantly, the levels of 
RANK mRNA were significantly increased in 
the uncultured BMMs from 11 MM patients 
compared to those from the uncultured BMMs 
from 6 NDs (Fig 2C). Because RANK 
expression is a critical step for generating 
osteoclast precursors, these results suggest that 
MM cells greatly promote early osteoclast 
differentiation. Surprisingly, although RANK is 
a marker of osteoclast precursors, we found that 
its expression continued to increase even in the 
terminally differentiated osteoclast cultures from 
MM patients (i.e., in the presence of RANKL for 
21d) (Fig 2D). Western blot analysis confirmed 
that the level of RANK protein was increased in 
the RANKL-differentiated MM relative to ND 
BMM cultures (Fig 2E). 
Critical role of AKT in RANK expression 
and osteoclast formation in BMM cultures from 
MM patients.  While the above results clearly 
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showed that RANK expression was up-regulated 
in osteoclast precursors from MM patients, the 
underlying mechanisms remain unknown. 
Recent studies showed that AKT plays a role in 
promotion of early osteoclast differentiation 
(24,25). We investigated whether AKT is 
up-regulated in the MM BMM cultures. As 
shown in Fig 3A, in the RANKL-differentiated 
MM BMM cultures, the levels of both 
phospho-AKT and total AKT proteins were 
up-regulated compared to those in the ND BMM 
cultures. Because RANK and AKT were 
similarly up-regulated in the MM BMM cultures, 
we determined whether AKT is required for the 
up-regulation of RANK expression in the MM 
BMM cultures. Results showed that LY294002, 
a specific AKT inhibitor, dose-dependently 
decreased RANK mRNA expression in the MM 
BMM cultures (Fig 3B). In contrast, the 
inhibitor did not reduce the expression of PU.1 
mRNA in the MM BMMs (Fig 3B). LY294002 
similarly decreased RANK protein expression in 
the MM BMM cultures in a dose-dependent 
manner (Fig 3C). Importantly, the AKT inhibitor 
blocked formation of the MNCs in the MM 
BMM cultures (Fig 3, D-F). Further, 
overexpression of a constitutively active form of 
AKT (AKT-CA) increased the mouse Rank 
promoter activity in COS-7 cells (Fig. 3F). 
Taken together, these results suggest that MM 
may activate RANK expression and osteoclast 
formation through, at least in part, up-regulation 
of AKT in osteoclast precursors. 
Soluble factors produced by MM cells 
increase AKT phosphorylation, RANK 
expression, and osteoclast formation. To 
determine whether MM cells produce soluble 
factors responsible for the increased AKT and 
RANK expression and osteoclast formation, 
primary mouse BMMs were treated with the 
conditioned media (CM) from human MM1.S or 
mouse 5TGM1 MM cell lines. Western blot 
analysis showed that AKT phosphorylation was 
increased by CM from both MM cell lines (Fig 
4A). The MM1.S-CM increased RANK 
expression at both the mRNA and protein levels 
in dose- and time-dependent manners (Fig 4, B 
and C). The MM1.S-CM dose-dependently 
promoted formation of both mononuclear and 
multinucleated osteoclasts (Fig 4, D and E). 
However, the MM1.S-CM did not alter the 
formation of colony-forming units 
granulocyte-macrophage (CFU-GM) (Fig 4, F 
and G), which contains the earliest osteoclast 
precursors (37).  
ATF4 protein is up-regulated in MM 
osteoclast cultures and by 5TGM1-CM and 
TNF-α. Our recent study demonstrates that loss 
of ATF4 impaired M-CSF induction of RANK 
expression in osteoclast precursors (25). 
Interestingly, we found that the level of ATF4 
protein was increased in the 
RANKL-differentiated BMM cultures from 4 
MM patients compared to that of 4 NDs (Fig 
5A). The level of ATF4 mRNA was not 
increased in MM versus ND cultures (Fig 5B), 
suggesting a post-transcriptional regulation. 
The 5TGM1-CM and TNF-α,  a well-known 
osteoclastogenic factor produced by many 
cancer cells including MM cells, increased the 
ATF4 protein levels in the BMM cultures (Fig 
5, C and E). In contrast, 5TGM1-CM and 
TNF-α did not increase the levels of Atf4 
mRNA (Fig 5, D and F). Interestingly, a slower 
migrating bands indicated by an arrow were 
observed in the MM BMM cultures (Fig 5A) 
and increased by treatments with 5TGM1-CM 
(Fig 5C) or TNF-α (Fig 5E). These bands are 
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probably phosphorylated forms of ATF4 
because similar bands in primary mouse 
BMMs disappeared with CIP phosphatase 
treatment (25).  
ATF4 is phosphorylated and 
up-regulated by AKT. To determine whether 
ATF4 is a downstream of AKT, we performed 
several experiments. First, we found that AKT 
inhibitor LY294002 decreased the ATF4 
protein levels in primary BMM cultures from 
MM patients in a dose-dependent manner (Fig 
6A). Second, overexpression of a constitutively 
active form of AKT (AKT-CA) increased the 
level of ATF4 protein in COS-7 cells (Fig 6B). 
There was a slower migrating ATF4 band on 
Western blots that was observed in samples 
from the AKT-CA-transfected cells (Fig 6B). 
Third, transfection assays revealed that 
AKT-CA increased ATF4-dependent 
transcriptional activity (Fig 6C), which was 
abolished by introduction of a 3-bp point 
mutation in the ATF4 binding core sequence 
(Fig 6D). Fourth, we tested whether ATF4 can 
be directly phosphorylayed by AKT enzyme by 
performing in vitro kinase assays using 
purified GST-ATF4 protein and AKT1 enzyme 
in the presence of [γ-32P]ATP. As shown in Fig 
6E, purified GST-ATF4 but not GST protein 
was directly and strongly phosphorylated by 
the AKT1 enzyme in vitro. Finally, adenoviral 
overexpression of ATF4 increased the level of 
Rank mRNA by 10-fold in osteoclast 
precursors (Fig 6F). In contrast, Dap-12 
(DNAX-activating protein 12), a membrane 
protein expressed in both macrophages and 
osteoclasts, was not increased by ATF4 in 
BMMs (Fig 6E).  
Blocking AKT reduces tumor burden in 
bone marrow cavity and inhibits the 
MM-induced osteoclast formation and 
osteolysis in SCID mice. To determine whether 
AKT plays a role in the MM-induced 
osteoclast formation and osteolysis in vivo, we 
injected 5TGM1 MM cells into the tibial 
marrow cavity of SCID mice. One week after 
the injection, animals were subcutaneously 
injected with LY294002 (40 mg/kg body 
weight) or vehicle (DMSO) twice per week for 
3 weeks. This LY294002 dose is in the range 
used by other investigators to efficiently block 
the PI3K/AKT pathway in mice (38,39). We 
examined whether the MM cells stimulated 
osteoclast formation by staining histological 
sections for the osteoclast enzyme 
tartrate-resistant acid phosphatase (TRAP). 
Results showed that 5TGM1 cells increased 
osteoclast surface/bone surface (Oc.S/BS) and 
osteoclast number/bone perimeter (Oc.Nb/BPm) 
of tibiae by 2.3- and 1.8-fold, respectively (P 
<0.05 for both, PBS/DMSO versus 
5TGM1/DMSO) (Fig 7, A-C). Strikingly, the 
MM-induced increases in Oc.S/BS and 
Oc.Nb/BPm were completely inhibited by 
LY294002 (Fig 7, A-C). We further 
determined whether blocking AKT affects the 
MM-induced osteolysis by examining 
histological sections. Results showed that, in 
DMSO-injected mice, the majority of the 
trabecular bone of the proximal tibial 
metaphysis was destroyed and that the marrow 
cavity was replaced by tumor tissues. In 
contrast, in those LY294002-injected mice, the 
bone destruction was largely prevented (Figure 
7, D and E). The formation of tumor tissues in 
bone marrow cavity was suppressed by AKT 
inhibition (Figure 7D). It should be noted that, 
although AKT was reported to regulate 
osteoclast and osteoblast function in mice (24), 
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the LY294002 treatment under our 
experimental conditions only slightly 
decreased the basal level of the Oc.S/BS (P = 
0.087, PBS/DMSO versus 5TGM1/LY). In 
addition, LY294002 did not cause any 
reductions in the Oc.Nb/BPm and trabecular 
bone area (P >0.12 for both parameters, 
PBS/DMSO versus 5TGM1/LY).  
AKT is critical for the MM cell growth 
and promotion of osteoclast formation in vitro. 
We next performed in vitro experiments to 
examine whether AKT pathway in the MM 
cells is required for the tumor cell growth and 
promotion of osteoclast formation. Results 
showed that the LY294002 treatment 
significantly decreased the growth of MM1.S 
cells in vitro (Figure 8A). Western blot 
analysis confirmed that the level of 
phospho-AKT but not total AKT protein was 
decreased by the AKT inhibitor (Figure 8B). 
Finally, osteoclast formation induced by the 
CM from MM1.S cells was significantly 
reduced by treatment of the tumor cells with 
LY294002 (Figure 8, C and D).  
DISCUSSION 
Abnormal osteoclast differentiation is a 
major contributor to osteolysis caused by major 
cancers such as MM, breast, lung and prostate 
cancers. Bone-residing cancer cells promote 
osteoclast formation and activation (16,40-45). 
Increased osteoclast formation and activity and 
bone resorption increase releases of growth 
factors from the bone matrix that stimulate 
cancer cell growth (40-46). Therefore, there is 
a vicious cycle between osteoclast-mediated 
osteolysis and tumor growth and progression in 
bone marrow. Breaking the vicious cycle is of 
major clinical significance since osteolytic 
lesions and related complications such as 
severe bone pain, pathological fractures, spinal 
cord compression, and hypercalcemia of 
malignancy are common causes of morbidity 
and sometimes mortality (42,47).  
In the present study, we found that 
AKT in osteoclasts and their precursors plays 
an important role in the MM promotion of 
osteoclast formation and activation and 
osteolytic lesions. Both AKT expression and 
phosphorylation are up-regulated in primary 
bone marrow osteoclast cultures from MM 
patients. Blocking AKT inhibits the 
MM-induced osteoclast formation in vitro and 
abolishes the MM-induced increase in 
osteoclast differentiation and osteolysis in bone. 
We demonstrate that AKT promotes osteoclast 
formation through, at least in part, 
up-regulation of RANK in osteoclast 
precursors. The expression of AKT and RANK 
are both increased in primary bone marrow 
osteoclast cultures from MM patients. AKT 
inhibition reduces the level of RANK mRNA 
and osteoclast formation in the MM BMM 
cultures. Overexpression of constitutively 
active form of AKT increases the RANK gene 
promoter activity. We further demonstrate that 
ATF4, which is up-regulated by AKT, TNF-α, 
and soluble factors produced by the MM cells, 
is a new upstream transcriptional activator of 
RANK gene expression in osteoclast 
precursors.  
Increased RANK expression in 
osteoclast precursors in the MM bone marrow 
could greatly increase the sensitivity for 
RANKL to induce osteoclast formation and 
maturation, suggesting that, even under low 
concentrations of RANKL, osteoclast 
differentiation can be enhanced in the bone 
marrow of MM patients. This notion is 
supported by the following evidence: i) 
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osteoclast formation is greatly enhanced in the 
MM BMM cultures in the absence of 
exogenously added RANKL, in which the 
RANKL/OPG ratio is reduced (Fig 1D); and ii) 
the levels of RANKL from many tumor cells 
that can activate osteoclast formation are very 
low (17). Furthermore, sustained high 
expression of RANK even in highly 
differentiated osteoclast cultures (i.e., 21d in 
the presence of RANKL) from MM patients 
could also suggest that part of the BMM cells 
in the MM bone marrow are maintained at the 
osteoclast precursor state because RANK 
expression is a marker of osteoclast precursors. 
These precursor cells can actively proliferate 
and increase the osteoclast numbers in bone 
marrow, which could further contribute to the 
increased osteoclast formation and osteolysis in 
MM patients.  
While results from the present study 
demonstrate that AKT is critical for the 
MM-induced osteoclast formation, how MM 
cells activate AKT remains unclear.  Cancer 
cells can produce and induce factors that can 
promotes osteoclast formation and activity, 
including granulocyte-macrophage 
colony-stimulating factor (GM-CSF) (16), 
monocyte chemotactic protein-1 (MCP-1) (17), 
macrophage inflammatory protein (MIP)-1α 
and MIP-1β (19,20), TNF-α (48), and PTHrP 
(14,15). Future studies will determine if any of 
those factors are responsible for MM cell 
activation of AKT in osteoclast precursors. It 
will be interesting to determine if AKT also 
mediates the osteoclast formation and 
osteolysis caused by other cancers such as 
breast, lung and prostate cancers in the future.  
It should be noted that blocking AKT in 
MM cells decreases their growth in vitro and 
that systemic inhibition of AKT blocks the 
formation of tumor tissues in the bone marrow 
cavity in SCID mice. Interestingly, our in vitro 
studies show that AKT inhibition in the MM 
cells also reduces the ability of tumor cells to 
activate osteoclast formation, which should 
contribute to the reduced osteoclast formation 
induced by the tumor cells. Finally, although 
the AKT inhibitor essentially abolishes the 
MM-induced osteolysis and bone loss, it does 
not significantly affect the basal level 
osteoclast formation and bone mass under our 
experimental conditions. Collectively, these 
results suggest that AKT could be a potential 
target for inhibiting the MM-induced osteoclast 
osteolytic lesions as well as tumor growth and 
progression, thus breaking the vicious cycle in 
the MM patients. 
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FIGURE LEGENDS 
Figure 1. Abnormal osteoclast differentiation in primary BMM cultures from MM patients in the 
presence and absence of exogenously added RANKL  
(A-C) Non-adherent BMMs from MM patients (MM) and normal donors (ND) were seeded at the 
density of 1x105/well on 96-well plate in α-MEM containing 20% horse serum and M-CSF (10 ng/ml) 
with or without RANKL (50 ng/ml) for 21d, followed by TRAP staining (A). TRAP-positive MNCs 
from (A) with (B) or without (C) RANKL treatment were scored under a microscope. Experiments were 
repeated at least 6 times using samples from different MM patients and NDs. Similar results were 
obtained. *P <0.01 (versus ND). (D-E) Non-adherent MM and ND BMMs were cultured in α-MEM 
containing 20% horse serum and M-CSF (10 ng/ml) without (D) or with (E) RANKL (50 ng/ml) for 21d 
as in (A), followed by qPCR analysis. mRNA levels were normalized to GAPDH mRNA. *P <0.01 
(versus ND). Experiments were repeated at least 3 times using samples from different MM patients and 
NDs. Similar results were obtained. (F) Non-adherent BMMs from 5 different MM patients and 5 
different NDs were cultured in α-MEM containing 20% horse serum and M-CSF (10 ng/ml) and 
RANKL (50 ng/ml) for 21d as in (A), followed Western blot analysis. β-ACTIN was used for a loading 
control for Western blot analysis.  
Figure 2. RANK expression levels are dramatically up-regulated in uncultured, undifferentiated 
and RANKL-differentiated BMMs from MM patients  
(A and B) MM and ND BMMs were seeded at the density of 1x106/dish into 35-mm dish in α-MEM 
containing 20% horse serum and proliferated by 10 ng/ml M-CSF for 10d, followed by qPCR (A) and 
Western blot analysis (B). Experiments were repeated at least 3 times using samples from different MM 
patients and NDs. Similar results were obtained. *P <0.01 (versus ND). (C) RNAs from uncultured 
BMMs from 11 MM patients and 6 NDs were used for qPCR analysis for RANK mRNA. *P <0.01 
(versus ND). (D) MM and ND BMMs were seeded at the density of 1x106/dish on 35-mm dish in 
α-MEM containing 20% horse serum and 10ng/ml M-CSF with or without 50 ng/ml RANKL for 21d, 
followed by qPCR analysis for RANK mRNA. Experiments were repeated at least 3 times using samples 
from different MM patients and NDs. Similar results were obtained. *P <0.01 (versus ND). (E) BMMs 
from 3 MM patients and 3 NDs were differentiated for 21d as in Figure 1F, followed by Western blot 
analysis for RANK protein.  
Figure 3. AKT is up-regulated and is critical for RANK expression and osteoclast formation in the 
MM BMM cultures  
(A) BMMs from 3 MM patients and 3 NDs were differentiated for 21d as in Figure 1F, followed by 
Western blot analysis for total and phosphor-AKT using specific antibodies. (B and C) BMMs from MM 
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patients were differentiated for 10d. On day 11, cells were treated by the indicated concentrations of 
LY294002 for 24h, followed by qPCR (B) or Western blot analysis (C). (D) BMMs from MM patients 
were differentiated for 10d. On day 11, cells were treated by LY294002 for 24h and switched to 
differentiation media for another 10d, followed by staining for the 23C6+ (top) and TRAP+ (bottom) 
MNCs. (E and F) Statistical analysis of (D). *P <0.01 (vs. 0 µM LY). (G) COS-7 cells were 
co-transfected with RANK-luc, in which a -1073/+79 mouse Rank gene promoter driving firefly luciferase 
gene expression, pRL-SV40 (for normalization) and indicated amounts of pCMV/AKT-CA or 
pCMV/β-gal, followed by dual luciferase assays. Experiments for B-F were repeated 2-4 times and 
similar results were obtained. 
Figure 4. Conditioned media from MM cell line cultures increase AKT phosphorylation, RANK 
expression, and osteoclast formation  
(A) Primary mouse BMMs were treated with equal volume of conditioned media (CM) from human 
MM1.S or mouse 5TGM1 MM cell lines or control medium (DMEM containing 2% FBS) for the 
indicated times, followed by Western blot analysis. (B) Primary mouse BMMs were treated with 
MM1.S-CM (0, 1/1000, 1/100, v/v) for 48h, followed by qPCR analysis for Rank mRNA. (C) Primary 
mouse BMMs were treated with MM1.S-CM (1/100, v/v) for the indicated times, followed by Western 
blot analysis for RANK protein. (D and E) Primary mouse BMMs were differentiated by M-CSF and 
RANKL in the presence or absence of indicated amounts of MM1.S-CM for 7d, followed by TRAP 
staining. TRAP-positive mononucleated (D) and multinucleated (3≥nuclei/cell) (E) osteoclasts (MNCs) 
were counted. *P<0.01 (vs. 0 MM1.S-CM). (F) CFU-GM assay. 2 x104 cells from mouse spleens were 
cultured in methylcellulose semi-solid medium in 35-mm dishes in the presence of 1.0 ng/ml of 
recombinant human GM-CSF in the presence or absence of indicated amounts of MM1.S-CM for 10d. 
The numbers of CFU-GM colonies were counted under an inverted microscope. (G) Statistical analysis of 
(F). Experiments for A-D were repeated 2-4 times and similar results were obtained. 
Figure 5. ATF4 protein is up-regulated in MM BMM cultures and by 5TGM1-CM and TNF-α .  
(A) BMMs from 4 MM patients and 4 NDs were differentiated by M-CSF and RANKL for 21d as in 
Figure 1F, followed by Western blot analysis. β-ACTIN was used for a loading control. (B) BMMs from 
1 MM patients and 1 ND were differentiated by M-CSF and RANKL for 21d as in Figure 1F, followed by 
qPCR analysis. ATF4 mRNA levels were normalized to GAPDH mRNA. (C-F) Primary mouse BMMs 
were cultured in M-CSF-containing media for 3d and treated with 5TGM1-CM for the indicated times (C 
and D) or the indicated concentrations of TNF-α for 48 h (E and F), followed by Western blot (C and E) 
or qPCR analysis (D and F). The mRNAs were normalized to Gapdh mRNA. Experiments for B-F were 
repeated 2-3 times and similar results were obtained. 
Figure 6. Effects of AKT activation or inhibition in the ATF4 expression and activity and 
phosphorylation  
(A) Non-adherent BMMs from MM patients were differentiated for 10d. On day 11, cells were treated by 
the indicated concentrations of LY294002 for 24h, followed by Western blot analysis for ATF4 
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expression. (B) COS-7 cells were co-transfected with pCMV/ATF4 and increasing amounts of expression 
vectors for a constitutively active form of AKT (AKT-CA), followed by Western blot analysis for ATF4 
and AKT. (C and D) COS-7 cells were co-transfected wild-type (wt) (C) and mutant (mt) (D) ATF4 
reporter plasmid (pOSE1-luc) (49), pRL-SV40 (for normalization), pCMV/ATF4 with or without the 
indicated amounts of AKT-CA expression vector, followed by dual luciferase assays.  *P<0.01 versus 0 
µg AKT-CA. (E) Purified GST-ATF4 and GST proteins were incubated with AKT1 (Cell Signaling 
Technology, Inc., Beverly, MA) in the presence of [γ-32P]ATP. (F) Primary mouse BMMs were cultured 
in M-CSF-containing media for 3d and infected with equal amounts of ATF4 or EGFP adenovirus. 
Twenty hours later, cells were harvested for qPCR for Rank and Dap-12 mRNAs. The mRNAs were 
normalized to Gapdh mRNA. *P <0.01 versus Ad/EGFP. Experiments for A-F were repeated 2-3 times 
and similar results were obtained. 
Figure 7. Blocking AKT inhibits the MM-induced osteoclast formation and bone loss and the tumor 
tissue formation in bone marrow cavity in SCID mice 
(A-C) 1x106 5TGM1 cells in 20 µl PBS or equal volume PBS alone were injected into both left and right 
tibiae of 4-weeks-old male SCID mice (10 mice/group or 20 tibiae/group). One week later, mice were 
subcutaneously injected with LY294002 (40 mg/kg body weight) or equal volume of vehicle (DMSO) 
twice a week for 3 weeks. Osteoclast surface/bone surface (Oc.S/BS) and osteoclast number/bone 
perimeter (Oc.Nb/BPm) of tibiae were measured using an Image Pro Plus 7.0 software as previously 
described (25). (D and E) Tibiae from each group were sectioned from the midtibial metaphysis for at 
least 10 sections from each tibia (6 tibiae/group) and stained with H&E. Trabecular bone area versus total 
bone marrow area was measured using an Image Pro Plus 7.0 software. *P <0.01 (vs. PBS/DMSO), 
#P<0.01 (vs. 5TGM1/DMSO).  
Figure 8. Blocking AKT inhibits the growth of MM cells and reduces their ability to activate 
osteoclast differentiation in vitro 
(A) MM1.S cells were seeded at 5x103/well on a 96-well plate and cultured for 2d in 10% FBS DMEM. 
Cells were then treated with LY294004 (10 µm) or equal volume of vehicle (DMSO) for the indicated 
times followed by the MTS assay as previously described(35). *P < 0.05, versus DMSO. (B) MM1.S 
cells were seeded at 5x105/dish on 6-well plate and cultured for 2d in 10% FBS DMEM and then treated 
with LY294004 (10 µm) or DMSO for 2d, followed by Western blotting. (C and D) MM1.S cells were 
seeded in 10% FBS DMEM media and treated with or without LY294004 (10 µM) or equal volume 
vehicle (DMSO) for 24h. Cells were then switched to 2% FBS DMEM media for another 24h. 
Conditioned media (CM) from each group were harvested. 2% FBS DMEM was used as control. For in 
vitro osteoclast differentiation, primary mouse BMMs were differentiated by M-CSF (10 ng/ml) and 
RANKL (30 ng/ml) in the presence of equal volume of the indicated CMs or control media (1/200, v/v) 
for 7d, followed by TRAP staining (C). TRAP-positive MNCs (3≥nuclei/cell) were counted (D). 
Experiments for A-D were repeated 2 times and similar results were obtained. *P <0.05 (vs. Ctrl Media), 
#P <0.05 (vs. MM1CM/DMSO). 
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Table 1: human qPCR primers 
Table 2: mouse qPCR primers 
Name 5’ primer 3’ primer 
Atf4 GAGCTTCCTGAACAGCGAAGTG TGGCCACCTCCAGATAGTCATC 
Dap12 GCCTGGTCTCCCGAGGTCAAG TCTGGTCTCTGACCCTGAAGCTCC 
Gapdh CAGTGCCAGCCTCGTCCCGTAGA CTGCAAATGGCAGCCCTGGTGAC 
Rank AGAGGGGAGCCTCAGGGTCC AAGTTCATCACCTGCCCGCTAGA 
Name 5’ primer 3’ primer 
ATF4 GGCTCCTCCGAATGGCTGGCTG CCATTTTCTCCAACATCCAATCTGTCC 
β3 GCAATGGGACCTTTGAGTGT ACATGCAGGTGTCAGTACGC 
CATK ACCGGGGTATTGACTCTGAA GAGGTCAGGCTTGCATCAAT 
DAP-12 GAGACCGAGTCGCCTTATC ATACGGCCTCTGTGTGTTG 
cFMS CAGAGCCAGGACTATCAATGC CTGGCTGAGCACACGATCT 
cFOS AAGGAGAATCCGAAGGGAAAGGAAT
AAGATGGCT 
AGACGAAGGAAGACGTGTAAGCAGTG
CAGCT 
GAPDH TCCACCACCCTGTTGCTGTA ACCACAGTCCATGCCATCA 
MMP-9 CCTTCACTTTCCTGGGTAAG CCATTCACGTCGTCCTTATG 
NFATc1 GCATCACAGGGAAGACCGTGTC GAAGTTCAATGTCGGAGTTTCTGAG 
PU.1 CAGAAGACCTGGTGCCCTAT GGAGCTCCGTGAAGTTGTTC 
RANK ATGCGGTTTGCAGTTCTTCTC ACTCCTTATCTCCACTTAGG 
TRAF6 TTG TGC TAG TGC CCT CGA GAA CTG GAG GAA AAA CTG GGG TGA 
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